Abstract:Background: Achieving the maximum reduction in cardiovascular morbidity and mortality is the primary goal of blood pressure (BP) control. Current guidelines recommend several antihypertensive classes as first-line therapy for this purpose but the decision on which agent/s to use will likely be based upon the treating physician's clinical experience. Observational studies provide a useful way of ascertaining the efficacy and tolerability of an antihypertensive in a real-life clinical setting. Objective: The aim of this observational study was to determine the efficacy, tolerability and physician/patient satisfaction with long-acting nifedipine (gastrointestinal therapeutic system [GITS]/osmotic-controlled release oral delivery system [OROS]) in a large multinational cohort of hypertensive patients. Methods: This observational study was conducted in adults (aged >= 18 years) with previously untreated or treated hypertension. The decision to prescribe nifedipine 30 or 60 mg once daily was made by the treating physician. Patients then attended up to three clinic visits any time over a 12-week period when medication could be up- or down-titrated or switched. The mean reduction in systolic BP (SBP)/diastolic BP (DBP) from first visit and whether target BP (<140/<90 mmHg or <130/<80 mmHg [for patients with diabetes mellitus]) had been achieved were recorded at the final visit and stratified according to hypertension grade and presence of cardiovascular risk factors. Subjective assessment of efficacy was reported by physicians and patients. All adverse events and their possible relationship to study drug were recorded. All assessments were performed on patients who received at least one dose of nifedipine GITS/OROS. Results: A total of 14 344 patients received nifedipine GITS/OROS treatment (58.7% male; 77.7% non-diabetic; mean age 57.5 years); 14 266 had at least one follow-up visit over a mean 10.2-week period, and 8000 patients had three visits over a mean 12-week period. Initially, 12 826 (89.4%) patients received nifedipine 30 mg, and 6912 patients (48.2%) overall received concomitant antihypertensive agents. The overall mean reduction in SBP/DBP was -27.7/-14.1 mmHg; BP reduction was linked to hypertension grade, age, the presence of five or more cardiovascular risk factors, and prior treatment. Target BP was achieved in 2485/7432 patients (33.4%) receiving nifedipine GITS/OROS monotherapy and in 1751/6912 (25.3%) receiving combination therapy (i.e. GITS/OROS plus any other antihypertensive agent). Non-diabetic patients with moderate (n = 3413) and high (n=1138) risk reached their target BP goal in 62.5% and 54.2% of cases, respectively; the corresponding values in diabetic patients (moderate-added risk n = 8; high-added risk n = 684) were 75.0% and 54.8%, respectively. A total of 229 patients (1.6%) reported experiencing 286 adverse events. Physician/patient satisfaction with treatment was high. Conclusion: Long-acting nifedipine GITS/OROS, alone or in combination with other antihypertensive agents, provides effective and well tolerated treatment of hypertension in a broad spectrum of patients routinely seen in day-to-day clinical practice.

Efficacy and Tolerability of Long-Acting Nifedipine GITS/OROS Monotherapy or Combination Therapy in Hypertensive Patients

Efficacy and tolerability of long-acting nifedipine GITSOROS monotherapy or combination therapy in hypertensive patients: Results of a 12-week international, prospective, multicentre, observational study

Efficacy of Different Doses of Nitroglycerin Combined with Clopidogrel in the Treatment of Angina Pectoris

Effectiveness and Tolerability of Nifedipine GITS in Patients with Chronic Kidney Disease and Uncontrolled Hypertension: A Prospective, Multicenter, Observational Study (ADRENAL)

[PP.02.03] EFFICACY AND TOLERABILITY OF NIFEDIPINE GASTROINTESTINAL THERAPEUTIC SYTEM 60MG IN CHINESE PATIENTS WITH UNCONTROLLED HYPERTENSION

Double-Blind, Multicenter, Active-Controlled, Randomized Clinical Trial to Assess the Safety and Efficacy of Orally Administered Nicorandil in Patients with Stable Angina Pectoris in China

Effects of Atenolol and Diltiazem-Sr on Quality of Life in the Hypertensive Patients

Efficacy And Safety Of Nifedipine Gits In Asians With Hypertension - Results Of A Post-Marketing Surveillance Study In China

BLOOD PRESSURE CONTROL OF NIFEDIPINE GITS 60MG TREATMENT IN PREVIOUSLY UNCONTROLLED HYPERTENSIVE PATIENTS: A PROSPECTIVE, OPEN-LABEL, MULTICENTER, SINGLE-ARM, 8WEEK STUDY

BLOOD PRESSURE CONTROL OF NIFEDIPINE GITS 60MG TREATMENT IN PREVIOUSLY UNCONTROLLED HYPERTENSIVE PATIENTS

Efficacy and safety of nifedipine GITS in Chinese patients with hypertension--a post-marketing surveillance study.

Effect of nifedipine controlled released tablet and atorvastatin on carotid intimamedia thickness and vascular endothelial function in patients with hypertension

Clinical effect and safety of nifedipine controlled-release tablets combined with valsartan in the treatment of primary hypertension

Efficacy and Safety of Nifedipine GITS in Asians with Hypertension

Efficacy, Safety and Tolerance of Felodipine Controlled Release Tablets and Felodipine Controlled Release Tablets Associated Combination Therapy in the Treatment of Mild to Moderate Essential Hypertension in China

Efficacy and Safety of Fixed Combination of Nitrendipine and Atenolol in Treatment for Patients with Mild to Moderate Essential Hypertension and Their Optimal Dosage Matching

Effects of Telmisartan Combined with Nifedipine Controlled Release Tablet on Inflammatory Fac-Tors,vascular Endothelial Function and Left Ventricular Function in Patients with Coronary Heart Disease with Mild to Moderate Hypertension

Transdermal clonidine as an adjunct to nifedipine-GITS therapy in patients with mild-to-moderate hypertension

A18728 Combination of Amlodipine with Diuretics or Telmisartan in High-risk Hypertensive Patients

Comparative effectiveness of generic nifedipine versus Adalat long-acting nifedipine for hypertension treatment: A multi-institutional cohort study

[Efficacy and safety of low dose sublingual nifedipine dripping pills (5 mg) in the acute treatment of moderate and severe hypertension: a randomized, double-blind, positive-drug parallel-controlled, multi-center clinical study]